CRISPR plasmids targeting Pten and p53, alone and in combination, are delivered by hydrodynamic injection to the liver; the CRISPR-mediated mutations phenocopy the effects of deletions using Cre–LoxP technology, allowing the direct mutation of tumour suppressor genes and oncogenes in the liver using the CRISPR/Cas system, which presents a new approach for rapid development of liver cancer models and functional genomics.
- Wen Xue
- Sidi Chen
- Tyler Jacks
